VIZGEN
PrivateLast Round
Series E
Jan 8, 2026
Total Funding Raised
$221.2M
Momentum Score
75 /100
Company Overview
Vizgen is a biotechnology company that specializes in biomolecule profiling technology to enhance understanding of biological systems and diseases through spatially resolved, single-cell gene expression analysis in intact tissue slices.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Biotech Equipment, Medical Imaging, Precision Medicine, Data Visualization
Business Model
B2B
Customer Profile
Usage-Based SaaS, Hardware Sales, Services & Consulting, Government Contracts
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
VIZGEN Comps
Public and private peers based on sector, stage, and business model.
VIZGEN Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series E | Jan 8, 2026 | ||||
| Series D | Oct 9, 2024 | ||||
| Growth Equity | Mar 8, 2024 | ||||
| Series C | Jun 3, 2022 | ||||
| Series B | Jul 20, 2021 | ||||
Series B | Apr 7, 2021 |
Key People
Founding team and executive leadership
VIZGEN Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Sofina | Series C |
| ARCH Venture Partners | Series E |
| M Ventures | Series E |
| Northpond Ventures | Series E |
| ARCH Venture Partners | Series B, Series D, Series C, Series A, Series E |
| Blue Water Life Science Advisors | Series C |
| Novalis LifeSciences | Series C, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 8, 2026
$48M Series E round completed.
- Nov 17, 2025
Collaboration with Ultivue to serve big pharma customers and CROs.
VIZGEN Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about VIZGEN's valuation, stock price, and market status.
